Sector News

Biosimilars look like a good bet now. But will they later?

February 28, 2017
Life sciences

Companies are flocking to the biosimilars scene, eager to capture a piece of the market for the world’s best-selling biologic drug brands. But one CEO won’t be surprised if those biosim developers one day change their tune.

Allergan chief Brent Saunders thinks companies will eventually back away from the field—his own included. The Dublin drugmaker likely won’t venture further into the arena, beyond the four cancer copies it’s currently developing with Amgen, he told Bloomberg.

Why? While the market may seem wide open now, with only Novartis and Pfizer on the scene with marketed biosims, that’s not going to last. Once the plethora of companies with biosimilars still in development win their approvals, it’ll be pretty crowded. Eventually, small biosim makers working to catch up with the big guns will have to slash prices to nab a slice of revenue. And that, in turn, won’t do anyone any favors.

“It’s great for society, but it’s bad for business,” Saunders told the news service of the discounting competition will bring.

The way he sees it, the biosimilars industry could wind up one day looking like the generics industry, but with much higher R&D, legal and manufacturing costs.

That’s presumably not something Saunders would like to hang around for. Last year, he completed a $40.5 billion sale of his company’s generics unit to Teva Pharmaceutical, which is still struggling under generics price erosion despite the acquisition.

Current biosimilars makers have plenty of issues to deal with in the meantime. As some industry players have insisted, uptake for the meds won’t be as fast as that of regular generics, as they’re not as easy to substitute. Plenty of other hopefuls working to bring their products to market are also involved in legal tussles, and the FDA is still finding its regulatory footing, too.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.